Concepts (100)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Toxoplasmosis, Congenital | 5 | 2015 | 7 | 0.620 |
Why?
|
| Toxoplasma | 4 | 2017 | 6 | 0.440 |
Why?
|
| Muscular Dystrophy, Duchenne | 3 | 2022 | 7 | 0.440 |
Why?
|
| Toxoplasmosis | 2 | 2017 | 6 | 0.260 |
Why?
|
| Toxoplasmosis, Ocular | 1 | 2006 | 2 | 0.260 |
Why?
|
| Vision Disorders | 1 | 2006 | 19 | 0.250 |
Why?
|
| Leukodystrophy, Globoid Cell | 1 | 2005 | 1 | 0.240 |
Why?
|
| Encephalomyelitis, Acute Disseminated | 1 | 2005 | 3 | 0.240 |
Why?
|
| Antibodies, Protozoan | 4 | 2017 | 4 | 0.210 |
Why?
|
| Morpholinos | 1 | 2022 | 3 | 0.190 |
Why?
|
| Cognition Disorders | 1 | 2006 | 681 | 0.180 |
Why?
|
| Mobility Limitation | 1 | 2022 | 73 | 0.180 |
Why?
|
| Immunoglobulin G | 3 | 2017 | 67 | 0.170 |
Why?
|
| Registries | 1 | 2022 | 153 | 0.170 |
Why?
|
| Immunoglobulin M | 2 | 2017 | 11 | 0.170 |
Why?
|
| Child, Preschool | 5 | 2015 | 561 | 0.170 |
Why?
|
| Disease Progression | 1 | 2022 | 517 | 0.160 |
Why?
|
| Immunoassay | 2 | 2017 | 34 | 0.160 |
Why?
|
| Codon, Nonsense | 1 | 2017 | 3 | 0.140 |
Why?
|
| Oxadiazoles | 1 | 2017 | 7 | 0.140 |
Why?
|
| Infant, Newborn | 5 | 2015 | 526 | 0.140 |
Why?
|
| Point-of-Care Testing | 1 | 2017 | 26 | 0.130 |
Why?
|
| Infant | 5 | 2015 | 478 | 0.130 |
Why?
|
| Child | 5 | 2022 | 1148 | 0.120 |
Why?
|
| Hydrocephalus | 1 | 2015 | 14 | 0.120 |
Why?
|
| Family Health | 1 | 2015 | 29 | 0.120 |
Why?
|
| Cluster Analysis | 1 | 2015 | 38 | 0.120 |
Why?
|
| Fathers | 1 | 2015 | 21 | 0.120 |
Why?
|
| Hypotension | 1 | 2015 | 20 | 0.120 |
Why?
|
| Adolescent | 5 | 2022 | 1855 | 0.110 |
Why?
|
| Genotype | 1 | 2015 | 246 | 0.110 |
Why?
|
| Heart Failure | 1 | 2015 | 138 | 0.100 |
Why?
|
| Humans | 12 | 2022 | 22592 | 0.100 |
Why?
|
| Food Contamination | 1 | 2011 | 2 | 0.090 |
Why?
|
| Eating | 1 | 2011 | 45 | 0.090 |
Why?
|
| Male | 7 | 2022 | 12260 | 0.080 |
Why?
|
| Female | 7 | 2015 | 12734 | 0.080 |
Why?
|
| Prospective Studies | 2 | 2022 | 1476 | 0.080 |
Why?
|
| Visual Acuity | 2 | 2006 | 38 | 0.080 |
Why?
|
| Pregnancy | 3 | 2015 | 308 | 0.070 |
Why?
|
| Vision, Binocular | 1 | 2006 | 2 | 0.060 |
Why?
|
| Vision, Monocular | 1 | 2006 | 2 | 0.060 |
Why?
|
| Macula Lutea | 1 | 2006 | 3 | 0.060 |
Why?
|
| Wechsler Scales | 1 | 2006 | 11 | 0.060 |
Why?
|
| Intelligence Tests | 1 | 2006 | 13 | 0.060 |
Why?
|
| Pattern Recognition, Visual | 1 | 2006 | 13 | 0.060 |
Why?
|
| Antiprotozoal Agents | 1 | 2006 | 8 | 0.060 |
Why?
|
| Language Tests | 1 | 2006 | 29 | 0.060 |
Why?
|
| United States | 4 | 2017 | 1741 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2005 | 302 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 77 | 0.050 |
Why?
|
| Paraneoplastic Syndromes, Nervous System | 1 | 2002 | 1 | 0.050 |
Why?
|
| Thoracic Neoplasms | 1 | 2002 | 9 | 0.050 |
Why?
|
| Neuroblastoma | 1 | 2002 | 17 | 0.050 |
Why?
|
| Abdominal Neoplasms | 1 | 2002 | 16 | 0.050 |
Why?
|
| Prevalence | 2 | 2015 | 372 | 0.050 |
Why?
|
| Autoantibodies | 1 | 2002 | 60 | 0.050 |
Why?
|
| Vital Capacity | 1 | 2022 | 5 | 0.050 |
Why?
|
| Walk Test | 1 | 2022 | 10 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2015 | 1386 | 0.040 |
Why?
|
| Mass Screening | 1 | 2002 | 152 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2022 | 2954 | 0.040 |
Why?
|
| Chicago | 2 | 2015 | 788 | 0.040 |
Why?
|
| Time Factors | 1 | 2022 | 1247 | 0.040 |
Why?
|
| Dystrophin | 1 | 2017 | 1 | 0.030 |
Why?
|
| Developing Countries | 1 | 2017 | 12 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2017 | 9 | 0.030 |
Why?
|
| Global Health | 1 | 2017 | 29 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 2017 | 32 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2017 | 371 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 431 | 0.030 |
Why?
|
| Serogroup | 1 | 2015 | 1 | 0.030 |
Why?
|
| Agglutination Tests | 1 | 2015 | 4 | 0.030 |
Why?
|
| Systole | 1 | 2015 | 13 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2017 | 2915 | 0.030 |
Why?
|
| Ventricular Function, Left | 1 | 2015 | 32 | 0.030 |
Why?
|
| Walking | 1 | 2017 | 233 | 0.030 |
Why?
|
| Echocardiography | 1 | 2015 | 60 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2015 | 165 | 0.030 |
Why?
|
| Incidence | 1 | 2015 | 618 | 0.030 |
Why?
|
| Serotyping | 1 | 2012 | 8 | 0.020 |
Why?
|
| Virulence | 1 | 2012 | 8 | 0.020 |
Why?
|
| Adult | 2 | 2015 | 6826 | 0.020 |
Why?
|
| Oocysts | 1 | 2011 | 1 | 0.020 |
Why?
|
| North America | 1 | 2011 | 31 | 0.020 |
Why?
|
| Alleles | 1 | 2012 | 162 | 0.020 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2011 | 25 | 0.020 |
Why?
|
| Young Adult | 1 | 2015 | 1607 | 0.020 |
Why?
|
| Pyrimethamine | 1 | 2006 | 1 | 0.020 |
Why?
|
| Sulfadiazine | 1 | 2006 | 1 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2006 | 151 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2006 | 208 | 0.010 |
Why?
|
| Serologic Tests | 1 | 2002 | 8 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2002 | 64 | 0.010 |
Why?
|
| Age of Onset | 1 | 2002 | 71 | 0.010 |
Why?
|
| Recurrence | 1 | 2002 | 270 | 0.010 |
Why?
|
| Ataxia | 1 | 2002 | 75 | 0.010 |
Why?
|
| Comorbidity | 1 | 2002 | 423 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2002 | 752 | 0.010 |
Why?
|
| Cognition | 1 | 2006 | 915 | 0.010 |
Why?
|